Vera Therapeutics says ORIGIN 3 final efficacy data for TRUTAKNA in IgA nephropathy is set for late-breaking ASN Kidney Week 2026 talk

Bitget2026/10/02 13:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vera Therapeutics flagged final efficacy results from the Phase 3 ORIGIN 3 trial of TRUTAKNA in IgA nephropathy.
Results have not been presented yet; they are scheduled for a late-breaking opening plenary talk at ASN Kidney Week 2026 on Oct. 22.
The update is positioned as a confirmatory readout following accelerated approval tied to proteinuria reduction, a key regulatory risk for the franchise.
Separate interim data from the Phase 2 PIONEER basket study in adult IgA nephropathy, primary membranous nephropathy are slated for Oct. 24.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020924PRIMZONEFULLFEED9838694) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Goldman Sachs strategists have lowered their 12-month target for South Korea's KOSPI Index from 12,000 points to 9,000 points, representing a 25% decrease. Earlier this year, Goldman had raised the target multiple times. The latest downgrade is due to mounting concerns in the market over artificial intelligence (AI) trading.

智通财经•2026/10/25 10:51

Goldman Sachs dramatically lowers KOSPI target from 12,000 to 9,000 points, still insists there is 60% upside potential

AI investment has not ended; wealth is simply being redistributed.

404k•2026/10/25 09:19

After the new regulation, South Korean retail investors turned into monthly net buyers of leveraged ETF, betting on a rebound in chip stocks for the first time.

格隆汇•2026/10/25 04:31